Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma

Molecular targeting in cancer and the impact on personalised medicine

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction

Current treatment options in mRCC

Discussion: Additional treatment options impact first-line treatment of mRCC

What have we learned? Expert perspectives